{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:36:26Z","timestamp":1785814586457,"version":"3.56.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>With rapid advances in disease diagnosis and treatment, patients with cancer will achieve longer survival. Among female cancer survivors, oncologic treatments often lead to premature ovarian insufficiency, negatively impacting their health and quality of life. Hormone replacement therapy (HRT) may mitigate these effects; however, concerns remain regarding its impact on oncologic outcomes. Updating the evidence base could help healthcare providers identify patients who may benefit from HRT without an increased risk of recurrence. This review provides an updated overview of HRT in women with a history of cervical, endometrial, ovarian, and breast cancers. For cervical cancer, HRT is not contraindicated in either squamous cell carcinoma or adenocarcinoma, regardless of stage. For endometrial cancer, HRT is not contraindicated in early-stage disease with no residual tumor, although it should be avoided in low-grade endometrial stromal sarcoma. HRT is not contraindicated in epithelial ovarian cancer regardless of stage, except in low-grade serous carcinoma. Currently, HRT is contraindicated for breast cancer. This review highlights the need to promote long-term healthcare strategies for cancer survivors. A shift in focus beyond cancer cure toward lifelong health management is warranted.<\/jats:p>","DOI":"10.1093\/jjco\/hyaf092","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:19:39Z","timestamp":1748938779000},"page":"1000-1004","source":"Crossref","is-referenced-by-count":5,"title":["Hormone replacement therapy in female-specific cancer survivors: considerations beyond cancer cure"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4466-0820","authenticated-orcid":false,"given":"Tomoko","family":"Yoshihama","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-8326","authenticated-orcid":false,"given":"Daisuke","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine , Tokyo ,","place":["Japan"]},{"name":"International University of Health and Welfare Graduate School , Tokyo ,","place":["Japan"]},{"name":"Akasaka Sanno Medical Center , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yamagami","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"2025101605113304800_ref1"},{"key":"2025101605113304800_ref2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2016.11.006","article-title":"Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: a systematic review","volume":"53","author":"Overbeek","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2025101605113304800_ref3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/GME.0b013e3182976f46","article-title":"Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history","volume":"21","author":"Marino","year":"2014","journal-title":"Menopause"},{"key":"2025101605113304800_ref4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-term health consequences of premature or early menopause and considerations for management","volume":"18","author":"Faubion","year":"2015","journal-title":"Climacteric"},{"key":"2025101605113304800_ref5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(06)70869-5","article-title":"Survival patterns after oophorectomy in premenopausal women: a population-based cohort study","volume":"7","author":"Rocca","year":"2006","journal-title":"Lancet Oncol"},{"key":"2025101605113304800_ref6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025101605113304800_ref7","author":"WHO Classification of Tumours Editorial Board"},{"key":"2025101605113304800_ref8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/pathogens9050403","article-title":"The relationship between estrogen-related signaling and human papillomavirus positive cancers","volume":"9","author":"James","year":"2020","journal-title":"Pathogens"},{"key":"2025101605113304800_ref9","first-page":"1341","article-title":"Estrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters","volume":"30","author":"Bodner","year":"2010","journal-title":"Anticancer Res"},{"key":"2025101605113304800_ref10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0090-8258(87)90270-8","article-title":"Hormonal replacement therapy in patients after cervical cancer treatment","volume":"26","author":"Ploch","year":"1987","journal-title":"Gynecol Oncol"},{"key":"2025101605113304800_ref11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/13697137.2020.1826426","article-title":"Hormone replacement therapy and cervical cancer: a systematic review of the literature","volume":"24","author":"Vargiu","year":"2021","journal-title":"Climacteric"},{"key":"2025101605113304800_ref12","doi-asserted-by":"publisher","first-page":"E537","DOI":"10.1002\/ijc.27321","article-title":"Postmenopausal estradiol-progestogen therapy and risk for uterine cervical cancer","volume":"131","author":"Jaakkola","year":"2012","journal-title":"Int J Cancer"},{"key":"2025101605113304800_ref13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.maturitas.2020.01.005","article-title":"European menopause and Andropause society (EMAS) and international gynecologic cancer society (IGCS) position statement on managing the menopause after gynecological cancer: Focus on menopausal symptoms and osteoporosis","volume":"134","author":"Rees","year":"2020","journal-title":"Maturitas"},{"key":"2025101605113304800_ref14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.radonc.2018.03.003","article-title":"The European society of gynecological oncology \/ European Society for Radiotherapy and Oncology\/European Society of Pathology guidelines for the management of patients with cervical cancer","volume":"127","author":"Cibula","year":"2018","journal-title":"Radiother Oncol"},{"key":"2025101605113304800_ref15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/ijgc-2022-003861","article-title":"Prescription of hormone replacement therapy among cervical cancer patients with treatment-induced premature menopause","volume":"33","author":"Suzuki","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"2025101605113304800_ref16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ygyno.2017.09.009","article-title":"Hormone replacement therapy after treatment for cervical cancer: are we adhering to standard of care?","volume":"147","author":"Rauh","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025101605113304800_ref17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/GME.0000000000000357","article-title":"Hormone therapy after uterine cervical cancer treatment: a Swedish population-based study","volume":"22","author":"Everhov","year":"2015","journal-title":"Menopause"},{"key":"2025101605113304800_ref18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2188\/jea.JE20200416","article-title":"Updated trends in cancer in Japan: Incidence in 1985\u20132015 and mortality in 1958-2018-a sign of decrease in cancer incidence","volume":"31","author":"Katanoda","year":"2021","journal-title":"J Epidemiol"},{"key":"2025101605113304800_ref19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.pathol.2.010506.091905","article-title":"Endometrial carcinoma","volume":"2","author":"Di Cristofano","year":"2007","journal-title":"Annu Rev Pathol"},{"key":"2025101605113304800_ref20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","article-title":"Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a gynecologic oncology group study","volume":"24","author":"Barakat","year":"2006","journal-title":"J Clin Oncol"},{"key":"2025101605113304800_ref21","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/jcm10143165","article-title":"Hormone replacement therapy in endometrial cancer survivors: a meta-analysis","volume":"10","author":"Londero","year":"2021","journal-title":"J Clin Med"},{"key":"2025101605113304800_ref22","doi-asserted-by":"publisher","first-page":"CD008830","DOI":"10.1002\/14651858.CD008830.pub3","article-title":"Hormone replacement therapy for women previously treated for endometrial cancer","volume":"5","author":"Edey","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025101605113304800_ref23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000505427","article-title":"Does hormone replacement therapy impact the prognosis in endometrial cancer survivors? A systematic review [review]","volume":"98","author":"Di Donato","year":"2020","journal-title":"Oncology"},{"key":"2025101605113304800_ref24","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/cncr.23717","article-title":"Racial disparities in recurrence among patients with early-stage endometrial cancer: Is recurrence increased in black patients who receive estrogen replacement therapy?","volume":"113","author":"Maxwell","year":"2008","journal-title":"Cancer"},{"key":"2025101605113304800_ref25","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using estrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"},{"key":"2025101605113304800_ref26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ygyno.2020.01.035","article-title":"Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: a Society of Gynecologic Oncology (SGO) clinical practice statement: this practice statement has been endorsed by the North American Menopause Society","volume":"157","author":"Sinno","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2025101605113304800_ref27","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1111\/jog.15284","article-title":"Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: annual patient report for 2019 and annual treatment report for 2014","volume":"48","author":"Yoshino","year":"2022","journal-title":"J Obstet Gynaecol Res"},{"key":"2025101605113304800_ref28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ygyno.2015.07.109","article-title":"Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis","volume":"139","author":"Li","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2025101605113304800_ref29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/GME.0000000000000508","article-title":"Hormone therapy for ovarian cancer survivors: Systematic review and meta-analysis","volume":"23","author":"Pergialiotis","year":"2016","journal-title":"Menopause"},{"key":"2025101605113304800_ref30","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/AOG.0000000000001396","article-title":"Hormone use after nonserous epithelial ovarian cancer: Overall and disease-free survival","volume":"127","author":"Power","year":"2016","journal-title":"Obstet Gynecol"},{"key":"2025101605113304800_ref31","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025101605113304800_ref32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis","volume":"26","author":"Wong","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"2025101605113304800_ref33","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025101605113304800_ref34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2019.04.018","article-title":"Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynecological cancers","volume":"116","author":"Rousset-Jablonski","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025101605113304800_ref35","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"2025101605113304800_ref36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/13697130500487224","article-title":"Menopausal symptoms in women treated for breast cancer: The prevalence and severity of symptoms and their perceived effects on quality of life","volume":"9","author":"Gupta","year":"2006","journal-title":"Climacteric"},{"key":"2025101605113304800_ref37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10549-021-06117-7","article-title":"Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors","volume":"187","author":"Peate","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2025101605113304800_ref38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"key":"2025101605113304800_ref39"},{"key":"2025101605113304800_ref40","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/1471-0528.17511","article-title":"Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: scoping review and international consensus recommendations","volume":"130","author":"Nebgen","year":"2023","journal-title":"BJOG"},{"key":"2025101605113304800_ref41","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer\u2013is it safe?), a randomized comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"key":"2025101605113304800_ref42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2025101605113304800_ref43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone therapy after breast cancer: the Stockholm randomized trial","volume":"97","author":"Schoultz","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2025101605113304800_ref44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomized trial","volume":"49","author":"Fahl\u00e9n","year":"2013","journal-title":"Eur J Cancer"},{"key":"2025101605113304800_ref45","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(12)70075-X","article-title":"Conjugated equine estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the Women\u2019s Health Initiative randomized placebo-controlled trial","volume":"13","author":"Anderson","year":"2012","journal-title":"Lancet Oncol"},{"key":"2025101605113304800_ref46","doi-asserted-by":"publisher","first-page":"e00270","DOI":"10.1016\/j.crwh.2020.e00270","article-title":"Menopausal hormone therapy and breast cancer risk: all progestogens are not the same","volume":"29","author":"Lambrinoudaki","year":"2021","journal-title":"Case Rep Womens Health"},{"key":"2025101605113304800_ref47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/PPO.0000000000000595","article-title":"Hormone replacement therapy after breast cancer: it is time","volume":"28","author":"Bluming","year":"2022","journal-title":"Cancer J"},{"key":"2025101605113304800_ref48","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of the North American Menopause Society","volume":"30","author":"The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Advisory Panel","year":"2023","journal-title":"Menopause"},{"key":"2025101605113304800_ref49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12885-023-11789-z","article-title":"Efficacy and safety of traditional Chinese medicine in the treatment of menopause-like syndrome for breast cancer survivors: a systematic review and meta-analysis","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"2025101605113304800_ref50","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/AOG.0000000000005294","article-title":"Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer","volume":"142","author":"Agrawal","year":"2023","journal-title":"Obstet Gynecol"},{"key":"2025101605113304800_ref51","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1001\/jamaoncol.2023.4508","article-title":"Vaginal estrogen therapy use and survival in females with breast cancer","volume":"10","author":"McVicker","year":"2024","journal-title":"JAMA Oncol"},{"key":"2025101605113304800_ref52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10549-016-3827-7","article-title":"Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy","volume":"157","author":"Sulaica","year":"2016","journal-title":"Breast Cancer Res Treat"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/9\/1000\/63425440\/hyaf092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/9\/1000\/63425440\/hyaf092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:11:41Z","timestamp":1760605901000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/9\/1000\/8155758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":52,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,6,3]]},"published-print":{"date-parts":[[2025,9,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf092","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,6,3]]}}}